Cargando…

Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features

Interstitial pneumonia with autoimmune features (IPAF) is a special subtype of interstitial lung disease that has received worldwide attention. Krebs von den Lungen-6 (KL-6) and surfactant protein-A (SP-A) can be used as an important biomarker of interstitial lung disease, but its exact relationship...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Mingshan, Cai, Chuanxu, Zeng, Yifeng, Xu, Yifan, Chen, Huai, Hu, Haisheng, Zhou, Luqian, Sun, Baoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850699/
https://www.ncbi.nlm.nih.gov/pubmed/33530214
http://dx.doi.org/10.1097/MD.0000000000024260
_version_ 1783645491489144832
author Xue, Mingshan
Cai, Chuanxu
Zeng, Yifeng
Xu, Yifan
Chen, Huai
Hu, Haisheng
Zhou, Luqian
Sun, Baoqing
author_facet Xue, Mingshan
Cai, Chuanxu
Zeng, Yifeng
Xu, Yifan
Chen, Huai
Hu, Haisheng
Zhou, Luqian
Sun, Baoqing
author_sort Xue, Mingshan
collection PubMed
description Interstitial pneumonia with autoimmune features (IPAF) is a special subtype of interstitial lung disease that has received worldwide attention. Krebs von den Lungen-6 (KL-6) and surfactant protein-A (SP-A) can be used as an important biomarker of interstitial lung disease, but its exact relationship with IPAF is poorly understood. A total of 65 IPAF patients were included in the study and were followed up for 52 weeks. The KL-6 and SP-A were evaluated by chemiluminescence enzyme immunoassay. The above indicators were tested at 2 time points, baseline (the first admission of patients) and 52 weeks. We also collected the indicators of antinuclear antibodies and rheumatoid factor. Based on high-resolution computed tomography evaluations, patients were divided into: aggravation, stable, and improvement group. At same time, 30 age-matched normal people as normal control were recruited, the same information was collected. Correlations among the groups were compared and analyzed. The KL-6 and SP-A level in IPAF patients were significantly higher than normal controls (fold increase = 11.35 and 1.39, both P < .001) and differed significantly at baseline and 52 weeks in IPAF (difference ratio = 37.7% and 21.3%, P < .05, both). There were significant differences at baseline and 52 weeks (r values of aggravation, improvement, and stable groups for KL-6 were 0.705, 0.770, and 0.344, P = .001, .001, and .163, and for SP-A the r value were 0.672, 0.375, and 0.316, P = .001, .126, and .152). In aggravation group, KL-6 and SP-A were correlated with CT scores (both P < .05). Diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC), % predicted showed a progressive downward trend, with a significant difference at baseline and 52 weeks in IPAF patients (difference ratio = 23.8% and 20.6%, both P < .05). There was a significant correlation between KL-6 and FVC % predicted and DLCO (both P < .05), SP-A showed negatively correlated with DLCO, but not significantly correlated with FVC % predicted (P < .05 and .47). This study demonstrated that KL-6 and SP-A can reflect disease progression, and both 2 play a key role at reflection of lung epithelial cell injury and fibrosis degree in IPAF.
format Online
Article
Text
id pubmed-7850699
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-78506992021-02-02 Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features Xue, Mingshan Cai, Chuanxu Zeng, Yifeng Xu, Yifan Chen, Huai Hu, Haisheng Zhou, Luqian Sun, Baoqing Medicine (Baltimore) 6700 Interstitial pneumonia with autoimmune features (IPAF) is a special subtype of interstitial lung disease that has received worldwide attention. Krebs von den Lungen-6 (KL-6) and surfactant protein-A (SP-A) can be used as an important biomarker of interstitial lung disease, but its exact relationship with IPAF is poorly understood. A total of 65 IPAF patients were included in the study and were followed up for 52 weeks. The KL-6 and SP-A were evaluated by chemiluminescence enzyme immunoassay. The above indicators were tested at 2 time points, baseline (the first admission of patients) and 52 weeks. We also collected the indicators of antinuclear antibodies and rheumatoid factor. Based on high-resolution computed tomography evaluations, patients were divided into: aggravation, stable, and improvement group. At same time, 30 age-matched normal people as normal control were recruited, the same information was collected. Correlations among the groups were compared and analyzed. The KL-6 and SP-A level in IPAF patients were significantly higher than normal controls (fold increase = 11.35 and 1.39, both P < .001) and differed significantly at baseline and 52 weeks in IPAF (difference ratio = 37.7% and 21.3%, P < .05, both). There were significant differences at baseline and 52 weeks (r values of aggravation, improvement, and stable groups for KL-6 were 0.705, 0.770, and 0.344, P = .001, .001, and .163, and for SP-A the r value were 0.672, 0.375, and 0.316, P = .001, .126, and .152). In aggravation group, KL-6 and SP-A were correlated with CT scores (both P < .05). Diffusing capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC), % predicted showed a progressive downward trend, with a significant difference at baseline and 52 weeks in IPAF patients (difference ratio = 23.8% and 20.6%, both P < .05). There was a significant correlation between KL-6 and FVC % predicted and DLCO (both P < .05), SP-A showed negatively correlated with DLCO, but not significantly correlated with FVC % predicted (P < .05 and .47). This study demonstrated that KL-6 and SP-A can reflect disease progression, and both 2 play a key role at reflection of lung epithelial cell injury and fibrosis degree in IPAF. Lippincott Williams & Wilkins 2021-01-29 /pmc/articles/PMC7850699/ /pubmed/33530214 http://dx.doi.org/10.1097/MD.0000000000024260 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle 6700
Xue, Mingshan
Cai, Chuanxu
Zeng, Yifeng
Xu, Yifan
Chen, Huai
Hu, Haisheng
Zhou, Luqian
Sun, Baoqing
Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title_full Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title_fullStr Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title_full_unstemmed Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title_short Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features
title_sort krebs von den lungen-6 and surfactant protein-a in interstitial pneumonia with autoimmune features
topic 6700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850699/
https://www.ncbi.nlm.nih.gov/pubmed/33530214
http://dx.doi.org/10.1097/MD.0000000000024260
work_keys_str_mv AT xuemingshan krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT caichuanxu krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT zengyifeng krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT xuyifan krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT chenhuai krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT huhaisheng krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT zhouluqian krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures
AT sunbaoqing krebsvondenlungen6andsurfactantproteinaininterstitialpneumoniawithautoimmunefeatures